Fig. 5
MSCHC reduces inflammation and disease severity in a graft-versus-host disease (GVHD) mouse model in vivo. A Timeline of treatment regimen of PBMC injection and MSCs administration. B Clinical scoring of GVHD-bearing mice with saline (n = 5), MSCLC (n = 5) and MSCHC (n = 4) with MSC administration from day 21 post-PBMC injection as indicated by green line. C Human CD45 blood count in treatment groups. D Representative histology images of lung, colon, liver, kidney and skin from each treatment group. The presence of immune cell infiltrates indicated by red arrows. Wilcoxon matched-pairs signed-rank test was performed between selected pairs. *p ≤ 0.05; *** p ≤ 0.001; ns represents non-significant. There were originally 15 mice for the study, but human CD45 engraftment was not successful in one mouse on Day 17 post-PBMC injection, hence to be removed from the study